TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07804615: A Study to Evaluate the Efficacy, PK, Safety, and Tolerability of VIM0423 in Adults With Parkinson's Disease Tremor Insufficiently Responsive to Dopaminergic Therapy

Sponsor: Vima Therapeutics · Phase: PHASE2 · Area: CNS_NEUROLOGY · Target Enrollment: 80 pts

Competing Trials Overlap

14 Active Trials

Excess Burn Exposure

$2,987,600

Rescue Site Savings

+$1,978,800

Unlock Full NCT07804615 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07804615 Rescue Dossier →